Back to list

Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: Results from the A1chieve observational study

Siddharth Shah, Alexey Zilov, Rachid Malek, Pradana Soewondo, Ole Bech and Leon Litwak

Diabetes Research and Clinical Practice, Issue 3, Volume 94, pages 364 - 370

Received 20 September 2011, Revised 10 October 2011, Accepted 13 October 2011, Published online Nov-2011

Article view:

Conflicts of interest

Professor Shah is a member of an advisory board panel for Novo Nordisk. Dr. Zilov is an opinion leader and lecturer for Novo Nordisk. Professor Malek is an advisory board member and lectures for Novo Nordisk. Dr. Soewondo is on an advisory panel for Novo Nordisk. Dr. Bech is an employee of Novo Nordisk. Dr. Litwak lectures for Novo Nordisk. This study was sponsored by Novo Nordisk A/S Denmark. The sponsor took part in the development of the protocol, the process of data collection and analysis, funding of medical writing services, and in reviewing the manuscript, but not in participant selection, choice of therapies (study or otherwise), provision of therapies including insulin, or continuing clinical management of the participants.

Back to list